TPBG siRNA – Trophoblast Glycoprotein (Mouse)

PRODUCT OVERVIEW

Product Name	TPBG, siRNA
Full Product Name	TPBG siRNA (Mouse)
Product Gene Name	TPBG sirna
Product Synonym Names	5T4; Trophoblast glycoprotein; 5T4 oncofetal trophoblast glycoprotein; 5T4 oncotrophoblast glycoprotein
Host	Synthetic
Species Reactivity	Mouse
Form/Format	Lyophilized powder
Purity/Purification	> 97%
Specificity	TPBG siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage	Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight	46,451 Da
3D Structure	ModBase 3D Structure for Q9Z0L0
Negative Control	siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control	Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use	We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components	We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse TPBG gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for TPBG sirna	RNA Interference (RNAi)
Related Product Information for TPBG sirna	MBS8230683 is an siRNA targeting TPBG. Also known as TPBG siRNA (Mouse). Reactive in Mouse. Host: Synthetic. siRNA to inhibit TPBG expression using RNA interference
Other Notes	Small volumes of TPBG sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

ADDITIONAL DETAILS

NCBI/Uniprot data below describe general gene information for TPBG. It may not necessarily be applicable to this product.

NCBI GI #	258645109

NCBI GeneID	21983
NCBI Accession #	NP_001158264.1
UniProt Primary Accession #	Q9Z0L0
UniProt Secondary Accession #	Q3UPI2; Q6PE98; Q8BQA4
UniProt Related Accession #	Q9Z0L0
GenBank Nucleotide #	NM_001164792.1
NCBI Official Full Name	trophoblast glycoprotein
NCBI Official Synonym Full Names	trophoblast glycoprotein
NCBI Official Symbol	Tpbg
NCBI Official Synonym Symbols	5T4; WAIF1; AW495680
UniProt Protein Name	Trophoblast glycoprotein
UniProt Synonym Protein Names	5T4 oncofetal trophoblast glycoprotein; 5T4 oncotrophoblast glycoprotein; Wnt-activated inhibitory factor 1; WAIF1
Protein Family	Trophoblast glycoprotein
UniProt Gene Name	Tpbg
UniProt Synonym Gene Names	5t4; 5T4 oncotrophoblast glycoprotein; WAIF1
UniProt Entry Name	TPBG_MOUSE
NCBI Protein Information	trophoblast glycoprotein
UniProt Comments for TPBG	TPBG: May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a- dependent LRP6 internalization Protein type: Membrane protein, integral; Motility/polarity/chemotaxis Cellular Component: cell surface; membrane; endoplasmic reticulum; cytoplasm; plasma membrane; integral to membrane
Research Articles on TPBG	**1.** The surface expression of 5T4 marks the use of the CXCR4 rather than the CXCR7 receptor, with distinct consequences for CXCL12 exposure.
Precautions	All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer	While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note	Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.